Background: A recent large UK clinical trial demonstrated that positron-emission
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Introduction
Chemo-radiotherapy has become a mainstay of primary treatment for many patients with squamous-cell carcinoma of the head and neck. However, for patients with advanced nodal disease (stage N2 or N3) there remains variation in subsequent treatment management.
Evidence of persistent disease in nodes after neck dissection in up to 40% of patients, combined with some evidence of a survival advantage resulting from surgery, has led to many centres maintaining neck dissection as the preferred treatment strategy [1] [2] [3] . However, in the 30-45% of patients exhibiting complete response on imaging after chemo-radiotherapy, less than 10% go on to experience disease recurrence [4, 5] ; combined with recent improvements in imaging technology, this has led to the sporadic adoption of image-guided treatment strategies in some countries as a means of sparing low-risk patients from the morbidity and expense of unnecessary surgery.
A recent UK clinical trial (PET-Neck) was conducted to assess the clinical utility and costeffectiveness of a combined 18F-fluorodeoxyglucose (FDG) positron-emission tomography and computed tomography (PET-CT) guided management for patients with advanced squamous cell carcinoma [6] . The study found that, over the trial 2-year follow-up period, overall survival was similar among patients in the PET-CT arm compared to those who underwent planned neck dissection (84.9% vs. 81.5% respectively). In addition, mainly as a result of fewer operations (54 vs. 221), the intervention was associated with a 2-year costsaving of £1,492. Combined with a small increase (+0.08) in quality-adjusted life years (QALY), PET-CT guided management was found to be cost-effective over the 2-year trial horizon.
Uncertainty remains over the long-term cost-effectiveness of image-guided management.
Initial cost-savings associated with PET-CT (largely attributable to the lower procedural cost 7 compared to neck dissection; currently £649 vs. £3,548 respectively in the UK [7] ) may not translate into long term cost savings if surgery is merely delayed or if the rate of late-stage recurrence events requiring more aggressive treatments is increased. Wide-scale adoption of new and potentially expensive technologies requires robust evidence on both long term clinical effectiveness and cost-effectiveness, and local decision makers need to have a clear idea of financial implications. Full consideration of the downstream cost consequences of PET-CT, as well as the impact on patient mortality and quality of life, therefore needs to be addressed.
Here we report results of the PET-Neck study lifetime cost-effectiveness analysis, which, together with previously published clinical outcomes [6] , provides vital evidence for the viability of a PET-CT guided management strategy for this patient group.
Methods
Clinical trial
The PET-Neck study was a UK pragmatic multi-centre phase III randomised non-inferiority trial (ISRCTN 13735240). Full details of the trial have been previously published [6] . Briefly, 
Health economic analysis
The PET-Neck health economic evaluation consisted of two components: (i) a previously reported within trial (2-year) analysis [6] ; and (ii) a lifetime analysis (the focus of this paper), in which the cost-effectiveness of PET-CT management versus planned neck dissection is assessed over a lifetime horizon using a modified Markov model. guidance [8] . All analyses were conducted in R (version 3.1.2) [9] .
Lifetime decision model
A de novo decision analytical model was constructed to estimate cost-effectiveness over a lifetime horizon (truncated at 100 years). The model is split into two phases (see Figure 1 : Simplified lifetime decision model structure). In the initial 6-month treatment phase, patients in the standard care arm (arm A) receive planned neck dissection (ND) either before or after chemo-radiotherapy (CRT), whilst patients in the PET-CT management arm (arm B) receive 9 chemo-radiotherapy followed by a PET-CT scan at 10-12 weeks post-chemo-radiotherapy which dictates whether or not patients go on to receive neck dissection. Costs and QALYs for the treatment period of the model were derived using individual participant data from the first 6 months of the trial. After 6 months, a Markov model was used to capture the health and cost implications of disease recurrence, for which the trial provided limited data.
Treatment period
Over the initial 6-month treatment period, patient health-related quality of life was measured using patient responses to the EQ-5D-3L questionnaire (collected at baseline, 2 weeks post chemo-radiotherapy and at 3, 6, 12, and 24 months post-randomisation). Multiple imputation was used to impute missing EQ-5D values, and patient utility scores were assigned to each of the EQ-5D defined health states using standard UK tariffs [10] . QALYs were calculated by combining utility values with overall survival data, using the Kaplan-Meier method to account for loss to follow-up.
Patients' use of hospital resources (e.g. surgical procedures, radiotherapy, chemotherapy, severe adverse events, patient follow-up assessments and recurrence events) was determined using the trial case report forms. National unit costs (reported in online supplementary material, Table S1 ) were applied to each of the resource items and any costs reported in 2014 prices were inflated to year 2015 using a consumer price index inflation value of 1.005 [7] [11-13]. Bootstrap analysis (i.e. data sampling with replacement) was conducted to assess the impact of sampling uncertainty around the 6-month cost and QALY results.
Markov model
Outcomes beyond the 6-month treatment period were simulated using a cohort Markov- Model parameters were derived directly from trial data or from the literature using targeted searches where necessary (see Table 1 : Markov model parameters). The proportion of patients beginning in each state of the model was taken directly from the trial data on overall survival and recurrences after 6 months. The cost and utility of the disease free state was based on the average monthly cost and utility values for patients who remained disease-free over the trial follow-up period (6-24 months), and the cost of initial treatment for recurrences was based on trial data on treatments administered upon recurrence. For patients who recovered from local recurrences, ongoing costs were assumed to be equal to those in the disease free state, whilst for patients remaining in the distant recurrence state an ongoing cancer supportive care cost was applied, derived from the literature [14] . Utilities for local and distant recurrence states were similarly taken from the literature [15] . Mortality within the disease free and local recurrence states were assumed equal to general population mortality (taken from Office of National Statistics [16] ), multiplied by a factor of 20% derived from the literature [17] . Mortality within the distant recurrence state was determined by calibrating the model survival curve against the Kaplan Meier overall survival curve from the trial.
A key parameter in the model concerns the rate of primary recurrence over time. In the base case analysis, recurrence data from the trial extended follow-up was used to directly inform recurrence rates up to year five, with subsequent recurrence assumed to drop to zero in both arms (since recurrence at 5 years was observed to be approaching zero in both arms of the trial; see online supplementary material, Figure S1 ). Uncertainty around the rate of recurrence was captured by simulating 10,000 bootstrap data samples from the trial Kaplan Meier 11 survival data. In addition, a sensitivity analysis was conducted to explore the impact of allowing recurrences beyond year 5 by fitting parametric survival curves to the within-trial Kaplan Meier recurrence survival plots (full details in online supplementary material; see Table S2 and S3, and Figures S2-S4 ). Subsequent recurrence rates (i.e. secondary recurrence onwards) were derived from the literature [18] .
Analysis
Cost-effectiveness was determined using the Incremental Cost-Effectiveness Ratio (ICER), which represents the additional cost required to be spent on a new intervention in order to gain an additional unit of health (i.e. QALY). Treatments are considered cost-effective if the mean ICER falls below a given decision-makers willingness-to-pay per additional health unit;
here we adopt NICE's lower willingness-to-pay per additional QALY threshold of £20,000 per QALY. An intervention that is more effective and less costly than standard care is considered dominant and in such cases the ICER is meaningless (as there is no trade-off between additional costs and health benefits to consider) and is therefore not reported.
All primary analyses used probabilistic sensitivity analysis to capture the impact of joint parameter uncertainty on the results, based on 10,000 Monte-Carlo simulations. Model parameters were represented by appropriate probability distributions, with a different set of parameter values randomly selected within each model simulation to produce a distribution of 10,000 cost and QALY results. A series of one-way sensitivity analyses (altering individual model parameters by + /-25% of their base case mean value) were also conducted.
A further sensitivity analysis was conducted adopting a broader NHS and PSS perspective.
This analysis used data on patients' use of secondary care outside of their enrolled hospital, as well as primary and community care, and was derived from patient reported resource-use forms used within the trial on a subset (n=42) of participants (full details in online supplementary data; results presented in figures S5 and S6). Since this analysis relied on data from a small subset of patients it is considered as exploratory only.
Results
PET-CT guided management was associated with a per-patient lifetime NHS secondary care cost saving of £1,485 [$2,133] (95% CI: -2,815 to 159) and a health gain of 0.13 (95% CI: -0.49 to 0.79) QALYs compared to planned neck dissection (see Table 2 : lifetime costeffectiveness results and Figure 2 : scatter plot) 1 . At a £20,000 [$28,736] per QALY threshold PET-CT was cost-saving 96% of the time, more effective than planned neck dissection 66%
of the time, and the most cost-effective strategy 75% of the time.
The level of uncertainty around the cost-effectiveness of PET-CT management over different willingness-to-pay per additional QALY thresholds is illustrated in the cost-effectiveness acceptability curve (CEAC) shown in Figure 3 . 2 The probability that the PET-CT management strategy is cost-effective remains above 67% up to a £150,000 [$215,517] per QALY threshold.
Broadening the analysis to an NHS and PSS perspective resulted in substantial increases in the overall costs in both arms, with an average saving of £700 in favour of PET-CT, and an 81% probability that PET-CT management is cost-effective at a £20,000 per QALY threshold (see Table 2 ). Allowing secondary and subsequent recurrences to occur beyond 5 years in the model led to a slight reduction in the expected additional QALYs to +0.10 (95% CI:-0.56 to 13 0.80), but PET-CT remained dominant with a 71% probability of being cost-effective (results presented in online supplementary material).
One-way sensitivity analysis
Results of the one-way sensitivity analysis are presented in Figure 4 . 3 The results are most sensitive to changes in relative rate of primary recurrences in each arm.
Discussion
In addition to verifying the effects on survival and recurrence rates, research into long-term health economic implications is critical in order to determine the overall value of treatment strategies by weighing up both cost and health outcomes at all points along the patient pathway.
This evaluation provides the first confirmation that PET-CT guided management is likely to provide a cost-effective alternative to planned neck dissection within a randomised setting in the longer term, and from a UK healthcare perspective. This adds support to the previous body of studies in favour of adopting PET-CT into routine clinical practice.
We found that, on average, PET-CT guided management is expected to produce long-term cost savings and improve patient outcomes, similar to results of the previously reported within-trial analysis [6] . The main difference is an increased level of uncertainty (with the probability that PET-CT management is cost-effective dropping from 99% to 75%), which is an expected consequence of any model attempting to extrapolate from short-term to long-term outcomes.
The findings are also in line with previous economic evaluations undertaken in non-randomised studies: in a recent study Pryor et al. found that a similar PET-CT guided strategy was a safe and significantly less costly alternative strategy to planned surgery from an Australian health service perspective [19] , and three studies have demonstrated cost-effectiveness from a United
States health care perspective [20] [21] [22] .
The results remained cost-effective over a range of sensitivity analyses. The notable exception is when considering changes to the rate of primary recurrence. In the base case analysis, as a result of non-significantly different recurrence-free survival observed between treatment arms in the trial and zero primary recurrences assumed beyond five years, there was no resulting long-term negative consequences from averting surgery. Artificially raising the rate of recurrence in the intervention arm, however, has a predictably detrimental impact on the expected cost-effectiveness, with PET-CT management no longer being cost-effective when the rate of recurrence is increased by 25% in that arm.
A key limitation of our analysis concerns the limited NHS secondary care perspective adopted in the base case analysis. For patients with advanced nodal disease, it is highly probable that subsequent treatment management will take place in hospital, and we therefore expect this analysis to capture the key cost elements; it is preferable however that cost-effectiveness assessments should account for all resources which will be consumed as a result of implementing the new intervention. This restricted perspective was adopted as a result of a lack of sufficient data within the trial upon which to derive full NHS or societal costs and is a frequent problem encountered in cancer trials. We conducted a sensitivity analysis looking at potential impact on broader NHS costs using data on a subset of patients in whom additional resource use data was collected. It is encouraging that these exploratory results support the main findings; however these results need to be interpreted with caution due to the small sample size.
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Further limitations of the analysis relate to the quality of evidence from the literature used to inform several of the model parameters. As with any model, uncertainty is introduced when using disparate sources to inform model inputs, and finding quality sources to inform postrecurrence outcomes is a particular issue in such analyses due to the difficulty of capturing such data. We conducted a range of sensitivity analyses in order to identify any key uncertain parameters. As discussed, the results were found to be largely robust.
In conclusion, our study indicates that the use of PET-CT guided management for patients with advanced head and neck cancer after primary chemo-radiotherapy reduces lifetime costs and improves patient health outcomes. Whilst our analysis focuses on the UK, the results are likely to be relevant to international healthcare settings where clinical pathways and procedural costs are similar.
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Unit Costs applied to trial resource use data
Units costs applied to the trial resource use data in the economic analysis are presented in Table S1 . Note: prices are reported as given in the original source i.e. non-inflated. Medical oncology first face-to-face attendance.
Cardiology assessment £160 Cardiology first face-to-face attendance.
Respiratory assessment £186
Respiratory Medicine first face-to-face attendance.
Other assessment £196 General Medicine first face-to-face attendance.
Dental assessment £126
Dental Medicine first face-to-face attendance. Nasopharyngoscopy £114 Diagnostic Nasopharyngoscopy, 19 years and over. Fine needle aspiration £164 Minor Maxillofacial Procedures.
Surgery assessment £150
General surgery first face-to-face attendance.
CT scan £147 Computerised Tomography Scan, more than three areas.
PET-CT Scan £649 Nuclear Medicine, Category 8 (PET-CT).
MRI Scan £145
Magnetic Resonance Imaging Scan, one area, post contrast only, 19 years and over. 
X-ray £40
Nurse assessment £100
PSSRU 2014. [12] Assume an assessment is equivalent to 1 hour of contact time.
Palliative care assessment £97
Social other £37 Assume equivalent to speech/diet assessment.
Speech assessment £37
Assume an assessment is equivalent to 1 hour of contact time.
Dietician assessment
£37
As above.
Rehabilitation assessment £36 Assume equivalent to 1 hour of occupational therapist contact time. GP home visit £67 Assume equal to reported cost for 17 min surgery visit.
Psychology assessment
District nurse home visit (phone call)
£66 (11)
Assume each visit equal to 1 hour contact time and a call is equivalent to 10 mins of contact time. Social worker visit (phone call)
Physiotherapist visit (phone call)
£36 (6) As above.
Occupational therapist visit (phone call) £36 (6) As above.
Counsellor visit (phone call)
£50 (8) As above.
Home help service £24 (4)
Assume a visit is equal to 1 hr of weekday contact and a call is equivalent to 10 mins of this time.
Psychiatrist £138
Assume a visit is equal to 1 hr contact time and a call is equivalent to 10 mins of contact time.
Day centre £24 Assume equivalent to home help service visit.
Chemotherapy drug costs 5FU
£3.47 eMIT 2015. [11] 5g/100ml vial, 5%, size 1. 
PET-Neck within-trial time to recurrence plots
Time to recurrence by treatment arm within the extended 5-year PET-Neck trial follow-up period is shown in Figure S1 . For Kaplan-Meier analysis of recurrence, the time of recurrence was taken as the time from completion of radiotherapy to reported recurrence or to cancer death if there was no reported recurrence. 
Methods
In the base case analysis no recurrence events were assumed to occur beyond year five in the model. A sensitivity analysis was conducted assuming recurrences could occur beyond year five by fitting parametric survival curves to the within-trial recurrence free survival Kaplan Meier plots. Long term recurrence probabilities for the planned neck dissection arm were estimated using a Gompertz parametric survival curve fitted to the trial baseline Kaplan Meier data; a hazard ratio (HR) was then applied to this curve in order to derive survival within the PET-CT management arm (using the HR observed across the trial follow-up period= 1.008).
The Gompertz distribution was identified as the best fitting curve to estimate long term recurrence events (compared to the Exponential, Weibull, Gamma and Lognormal distributions), based on an analysis of AIC and BIC criteria (see Table S2 ; better fitting curves are indicated by lower AIC and BIC values) and a visual inspection of the curve fits (see Figure S2 : Plot of parametric survival curves (using Gompertz and Log-normal model specifications) against trial data on patient recurrence free survival). Figure S2 . Plot of parametric survival curves (using Gompertz and Log-normal model specifications) against PET-Neck trial data on patient recurrence free survival
Results
Results of the sensitivity analysis allowing primary recurrences beyond year five are presented in Table S3 (results table) , Figure S3 (scatter plot) and Figure S4 (costeffectiveness acceptability curve).
2,3 CI = confidence interval; QALY= quality adjusted life year; ICER= incremental cost-effectiveness ratio; ND= neck dissection; PET-CT= positron-emission tomography and computed tomography; Dominant= more effective and less costly than standard care (ICER not reported in these cases).
2 Figure S3 shows the incremental cost and quality adjusted life year (QALY) results for PET-CT management versus standard care for each of the 10,000 model simulations (i.e. the scattered dots).
The diagonal line represents a willingness-to-pay per additional QALY threshold of £20,000 per QALY. All points below this threshold line are considered cost-effective; points above this line are not considered cost-effective. The triangle indicates the mean incremental cost and QALY result. 
Sensitivity analysis: NHS & PSS perspective
Methods
In the base case analysis, costs were calculated using data from the trial case report forms which provided information on a range of secondary care resource usage for the total trial population (n=564). Additional data on primary and community care resource usage, as well as additional secondary care resource usage (outside of the enrolled oncology department), was collected for a subgroup of the trial population (n=42) enrolled at the two main recruiting centres. These patients were asked to recall their use of NHS and PSS services over the past 3 months (or since completion of the last form where appropriate) at baseline, during treatment (2 weeks post CRT), and at 3, 6, 12 and 24 months post randomisation. A sensitivity analysis was conducted to assess the potential impact of including this additional cost data, by imputing the mean reported values for the additional resource use items collected in the patient-reported forms to the total trial population. Mean values were calculated using a complete case analysis of the patient-reported data. Due to the small sample size it was deemed inappropriate to attempt to conduct multiple imputation for missing data.
Within the patient-reported questionnaires, patients were asked to report any additional visits to hospital (inpatient, day centre, outpatient, A&E or nursing home visits), not including visits to their enrolled oncology department; this was in order to capture additional secondary care resource usage not already captured in the case report forms routinely completed at the patient's enrolled oncology department. However, where additional hospital visits were reported, patients were asked to give the name of the hospital they visited, and a significant number of patients identified the hospital as the same as that to which they were enrolled in the trial. In such cases it was assumed that this data would already have been captured in the trial case report forms and these events were therefore excluded from the analysis.
Results
Results of the sensitivity analysis using an NHS and PSS perspective over a lifetime horizon are presented in Figure S5 (scatter plot) and Figure S6 (cost-effectiveness acceptability curve). Note: the results table for this analysis is reported in Table 2 in the main article text. 4, 5 Figure S5. Scatter plot of lifetime cost-effectiveness results using an NHS and PSS perspective 4 Figure S5 shows the incremental cost and quality adjusted life year (QALY) results for PET-CT management versus standard care for each of the 10,000 model simulations (i.e. the scattered dots).
